Lung cancer is currently the number one cause of cancer death worldwide, and the number is increasing every year, and its treatment is also receiving increasing attention, while non-small cell lung cancer (NSCLC) accounts for about 80% of lung cancer, and most patients are in advanced stage (stage III and IV) when they are diagnosed, and radiotherapy and chemotherapy are mainly used. Docetaxel is a semi-synthetic paclitaxel drug with the same mechanism of action as paclitaxel, and its stabilizing effect on microtubules is two times greater than that of paclitaxel. We chose docetaxel combined with cisplatin to treat 30 cases of III non-small cell lung cancer patients, which are reported as follows: Data and methods General data Thirty patients with stage III lung cancer in our hospital from January 2008 to February 2009 were selected and all were confirmed by pathological histological and/or cytological examination. Among them, 19 cases were male and 11 cases were female, and their ages ranged from 38 to 70 years. According to the international TNM clinical staging criteria, there were 13 cases of IIIA and 17 cases of IIIB. Pathological types: 18 cases of squamous carcinoma, 10 cases of adenocarcinoma, and 2 cases of mixed squamous-glandular carcinoma. All patients had no history of other anticancer drug applications or radiation therapy and were treated for the first time. Survival was expected to be more than 3 months, there were evaluable clinical or imaging observation indexes to evaluate the recent efficacy, and there were no abnormalities in blood routine, liver and kidney function, and electrocardiogram before and after treatment. Efficacy was evaluated after two cycles of chemotherapy. Treatment Docetaxel 75mg/O intravenous drip, 1 time/day, dexamethasone 5mg intramuscularly 1 day before the dose, after 1 to 3 days, intravenous push dexamethasone 10mg, a total of 4 days, to prevent the occurrence of allergy and edema; cisplatin 25mg/O intravenous drip, 1 time/1 to 3 days, 21 days a cycle. 30min before chemotherapy intramuscular injection of isoproterenol 25mg, IV cimetidine 400mg, give azathioprine for antiemetic, while hydration, diuresis, and support with colony stimulating factor if necessary. The efficacy and toxicity were evaluated by reviewing chest CT and other tests after completing 2 cycles. Criteria for efficacy evaluation and observation of toxic side effects Recent objective efficacy was classified as CR (complete remission), PR (partial remission), SD (stable) and PD (progressive) according to WHO criteria. Patients were checked for routine blood tests once or twice a week, liver and kidney function and electrocardiogram before each cycle of treatment, and a comprehensive examination was done at the end of the course of treatment. efficacy was assessed after 2 cycles. The efficacy was confirmed after 4 weeks for effective cases. Toxic side effects were graded from 0 to IV according to WHO standards. Results In the near-term efficacy of the whole group of 30 cases, there was one case of complete remission (CR), 13 cases of partial remission (PR), 11 cases of no change (NC), and 5 cases of progression (PD), with an overall effective rate (OR) of 40.6%. The long-term efficacy was 19 out of 30 patients survived for more than 1 year, with a 1-year survival rate of 63.3%. Toxic side effects were classified as 0~IV according to the WHO standard, which were mild and well tolerated by patients in the whole group. The incidence of the main side effects were myelosuppression, neutrophil decline, platelet decline and hemoglobin decline, which were 73.3% (22/30), 26.6% (8/30) and 43.3% (13/30), respectively. Prophylactic application of antiemetic drugs, diuretic and hepatoprotective drugs, gastrointestinal reactions and hepatic and renal impairment were mild, and all patients had varying degrees of hair loss. Discussion Most patients with non-small cell lung cancer (NSCLC) are clinically diagnosed at an intermediate to advanced stage, losing the chance of surgical resection, and are mostly treated with systemic chemotherapy. Chemotherapy can improve the quality of life and prolong the survival of patients with advanced NSCLC, and there is no other treatment alternative to chemotherapy. Chemotherapy drugs include vincristine, paclitaxel and gemcitabine. Docetaxel is a new generation chemotherapeutic agent of the paclitaxel class. Docetaxel is a semi-synthetic paclitaxel compound, which can promote microtubule aggregation and increase microtubule stability, with the same mechanism of action as paclitaxel, and its stabilizing effect on microtubules is two times greater than that of paclitaxel, with a broader anti-cancer spectrum and significant clinical efficacy in a variety of tumors. Cisplatin is considered to be one of the most basic drugs for non-small cell lung cancer, with a single agent efficiency of about 20%. According to a meta-analysis of 52 randomized clinical studies, cisplatin-based chemotherapy can significantly improve survival, and most of the current chemotherapy is platinum-based. The combination of docetaxel and cisplatin has an advantage over single agent treatment, and the long-term efficacy of 1-year survival rate was 63.3% in our group of 30 cases. The effective rate of docetaxel combined with cisplatin in this study was 40.6%. A once worrisome toxic side effect of this regimen was allergic reactions, but after prophylactic application of dexamethasone, none of the trials in this group had complications such as edema, indicating that the chance of serious allergic reactions after pretreatment was extremely low. In conclusion, the combination of docetaxel and cisplatin is safe and effective in the treatment of non-small cell carcinoma and is worthy of clinical promotion.